# DESCRIPTION

## FIELD OF THE DISCLOSURE

- relate biomarker to diabetes and cancer

## BACKGROUND

- introduce WD-repeat proteins
- describe WDR13 protein
- discuss beta cell mass regulation
- summarize cell cycle regulators
- relate insulin levels to obesity
- describe insulin resistance
- discuss obesity consequences

## DEFINITIONS

- define WD-repeat proteins

## SUMMARY

- summarize WDR13 as drug target
- describe mutant mouse strain
- show WDR13 as negative regulator
- describe enhanced beta cell proliferation
- discuss p21 down regulation
- describe WDR13 overexpression
- introduce biomarker for diabetes and cancer
- describe expression construct
- outline method for preparing tumor model
- summarize WDR13 uses

## DETAILED DESCRIPTION

### Examples

- introduce Wdr13 knockout mice generation
- describe targeting strategy for Wdr13 gene
- construct Wdr13 gene targeting vector
- electroporate targeting vector into ES cells
- select and identify targeted clones
- inject targeted clones into blastocysts
- obtain germline transmission of mutant allele
- confirm targeting of Wdr13 gene by northern and western blot
- show viability and fertility of Wdr13 knockout mice
- analyze litter size from various matings
- measure sperm number from Wdr13-/- males
- describe increased body weight of Wdr13 knockout mice
- measure body composition and organ weights
- observe adipocyte hypertrophy in Wdr13 knockout mice
- measure glucose and insulin levels in Wdr13 knockout mice
- determine glucose clearance and insulin sensitivity
- analyze pancreatic histology and islet mass
- measure beta cell proliferation by in-situ BrdU labeling
- conclude higher insulin level due to increased islet mass
- describe glucose clearance experiment
- measure insulin secretion in Wdr13−/0 mice
- isolate islets from Wdr13−/0 and wild type mice
- measure in vitro insulin secretion
- overexpress Wdr13 gene in MIN6 cell line
- monitor cell growth by MTT assay and cell counting
- perform western blot analysis
- analyze cell cycle regulators by western blotting
- perform chromatin immunoprecipitation experiment
- identify proteins interacting with WDR13
- analyze WDR13 protein structure
- overexpress FLAG-WDR13 fusion protein
- perform immunoprecipitation in Hela cells
- identify interacting partners by LC-MS/MS
- validate interaction of HDAC7 with WDR13
- test interaction of WDR13 with other HDACs
- validate interaction of WDR13 with nuclear receptors
- test interaction of WDR13 with PHIP1 and NR2E1
- perform co-immunoprecipitation experiment
- analyze functional significance of WDR13 interactions
- perform transient luciferase assay
- analyze repression of ERα and ERβ by WDR13
- describe statistical analysis
- provide ethics statement

## Discussion

- introduce WDR13 knockout mice
- describe body weight gain in mutant mice
- explain adipose tissue volume increase
- discuss insulin levels and glucose-stimulated insulin secretion
- relate body weight gain to insulin levels
- describe islet mass and insulin secretion
- discuss glucose clearance and insulin sensitivity
- suggest insulin hypersecretion is not a compensatory response
- relate WDR13 to feeding behavior and metabolism
- describe WDR13 expression in pancreas and pancreatic islets
- discuss increased islet mass in Wdr13 knockout mice
- explain enhanced beta cell proliferation
- discuss reversal of phenotype in pancreatic MIN6 cells
- describe various regulators of beta cell proliferation
- discuss WDR13 interaction with ERα, ERβ, PHIP1, and HDACs
- explain role of WDR13 in chromatin regulation
- discuss PHIP1 function in cell proliferation
- propose WDR13 and PHIP1 interaction in beta cell proliferation
- describe WDR13 repression of estrogen receptors
- discuss p21 regulation by WDR13 and estrogen receptors
- suggest WDR13 as a potential drug target for diabetes
- conclude WDR13 deficiency leads to increased beta cell mass and hyperinsulinemia

## Illustrative Advantages:

- summarize advantages of WDR13 as a novel protein

